Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



Can Merck's Breadth Beat AbbVie's and Pfizer's Focus?

Merck (NYSE: MRK  ) will release its quarterly report on Monday, and investors are expecting a continuing pullback in earnings that shows the difficulty the pharmaceutical giant has had in navigating its patent cliff. One big strategic question that shareholders will want answered is whether Merck expects eventually to follow moves by Pfizer (NYSE: PFE  ) and AbbVie (NYSE: ABBV  )  to try to unlock shareholder value through separating parts of their respective businesses and focusing on pharma.

This quarter, Merck will finally stop seeing the huge revenue hits that the loss of patent protection on Singulair has wrought throughout the past year. Yet that doesn't make it any less important for Merck to keep looking for prospective blockbuster treatments to replace that lost revenue. At the same time, though, Merck is also still looking to other markets like animal health and over-the-counter consumer health products to bolster sales, choosing not to follow Pfizer's and AbbVie's lead in splitting off similar businesses to focus exclusively on pharmaceuticals. Let's take an early look at what's been happening with Merck over the past quarter and what we're likely to see in its report.

Stats on Merck

Analyst EPS Estimate


Change From Year-Ago EPS


Revenue Estimate

$11.12 billion

Change From Year-Ago Revenue


Earnings Beats in Past 4 Quarters


Source: Yahoo! Finance.

When will Merck earnings grow again?
In recent months, analysts have cut their views on Merck earnings, reducing third-quarter estimates by $0.02 per share and pushing down their full-year 2014 projections by $0.15 per share. The stock has also moved down slightly, falling 2% since late July.

Merck's second-quarter earnings announcement in July showed the successes and challenges that the pharma giant has faced recently. The company managed to beat earnings estimates by a penny per share, but double-digit sales declines led to generally accepted accounting principles earnings getting cut almost in half. Asthma drug Singulair was responsible for just about all of those declines, with Merck's stable of other approved drugs failing to pick up the slack. Moreover, just as AbbVie must face the coming loss of patent protection for its key drug Humira, Merck has to deal with patents on major drugs Zetia, Vytorin, and Nasonex all expiring within the next three to four years, opening up more generic competition down the road.

As a result, Merck has scurried to get replacement drugs into its pipeline. Yet pipeline efforts have led to increased research and development expenses, raising Merck's total costs well above those of Pfizer and other industry rivals like Johnson & Johnson and GlaxoSmithKline. High expenses have led Merck to announce massive layoffs, but some question whether a smaller workforce can pull the company back to health.

Strategic partnerships could help Merck move forward with its pipeline development. Last month, Merck added to its ongoing relationship with AstraZeneca to develop Merck's MK-1775 experimental cancer drug. The move should allow Merck to focus on more promising cancer treatments, such as its vintafolide ovarian-cancer treatment in phase 3 studies in the U.S., as well as its MK-3475 drug for metastatic melanoma.

The larger question is whether Merck could better focus on its pharma opportunities without the distraction of its other businesses. Animal health is a substantial contributor to overall sales, with Merck controlling more than 15% of the $100 billion global market, second only to Pfizer spinoff Zoetis, and it offers huge growth potential as the world moves toward higher-protein diets. Yet the consumer-care division saw double-digit percentage sales declines in the second quarter, suggesting that Merck isn't doing that business any favors by keeping it under its broader umbrella rather than following the AbbVie and Pfizer model of focusing solely on pharma.

In the Merck earnings report, watch to see how the company responds to its massive challenges. A spinoff wouldn't solve its problems automatically, but it might make it easier for Merck to find solutions to resolve them in the long run.

Is Merck the best way to play the cancer-treatment space?
Merck has promise with its cancer treatments, but your best way to play the cancer space is to find companies that shun the status quo and instead discover revolutionary, groundbreaking technologies. In The Motley Fool's brand-new FREE report "2 Game-Changing Biotechs Revolutionizing the Way We Treat Cancer," find out about a new technology that big pharma is endorsing through partnerships, and the two companies that are set to profit from this emerging drug class. Click here to get your copy today.

Click here to add Merck to My Watchlist, which can find all of our Foolish analysis on it and all your other stocks.

Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2699551, ~/Articles/ArticleHandler.aspx, 9/26/2016 6:40:59 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated Moments ago Sponsored by:
DOW 18,094.83 -166.62 -0.91%
S&P 500 2,146.10 -18.59 -0.86%
NASD 5,257.49 -48.26 -0.91%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

9/26/2016 4:04 PM
ABBV $64.07 Down -0.91 -1.40%
AbbVie CAPS Rating: ****
MRK $62.15 Down -0.81 -1.29%
Merck and Co. CAPS Rating: ****
PFE $33.64 Down -0.62 -1.81%
Pfizer CAPS Rating: ****